Clinical application and market analysis of Axitinib: from mechanism to new trends in medical insurance

Renal cell carcinoma (RCC) is one of the most common urinary system malignancies in the world, accounting for more than 80% of adult renal malignancies. In the past decade, treatment modalities have experienced a leap from cytokine therapy, to targeted small molecule tyrosine kinase inhibitors (TKIs), to immune checkpoint inhibitors. Axitinib (trade name Inlyta®), as a highly selective VEGFR inhibitor, occupies a central position in this transformation process. Especially after combined application with immune drugs, its status has risen rapidly.

xa0

2. Latest indication progress: combination therapy significantly prolongs survival

Axitinib was initially approved as a second-line single agent for advanced RCC after failure of prior systemic therapy. But what really gives it a new lease of life is its powerful combination with immunotherapy.

Combined with pembrolizumab (Pembrolizumab): In the latest 5-year follow-up of the global phase III KEYNOTE-426 study, the combination of axitinib + pembrolizumab significantly extended the median overall survival to 47.2 months compared with traditional sunitinib, while the control group was only 40.8 months. The progression-free survival was 15.7 months vs 11.1 months respectively, and the objective response rate was also higher. This means patients not only live longer, but also have more stable disease control.

Combined with avelumab (Avelumab): This combination also showed significant progression-free survival benefit, especially in the PD-L1 positive population.

These data demonstrate that the value of axitinib has surpassed that of a single agent and has become an important pillar of immunotherapy regimens.

3. Usage and dosage: from fixed dose to individualized management

The usual recommended dose of axitinib is 5 mg twice daily, taken orally approximately 12 hours apart. Dosage management in clinical practice is more flexible than in package inserts:

Dose escalation strategy: If the patient tolerates it well, it can be gradually increased to7mg or 10mg, with at least two weeks between each increment. Studies have shown that some patients who tolerated the drug well had their progression-free survival extended to more than 16 months after the dose was increased.

Dose reduction: If serious adverse reactions occur, such as hypertension, diarrhea, hand-foot syndrome, etc., the dose can be reduced to3mg or even 2mg to ensure continuity of treatment.

Medicine Tips:

It can be taken with food or on an empty stomach, but foods that affect metabolism such as grapefruit juice should be avoided.

If you miss a dose or vomit, it is not recommended to take another dose. Continue with the next dose at the normal time.

The concept of individualized dose adjustment is highly consistent with precision medicine, emphasizing the balance between efficacy and safety.

xa0

xa0

4. Popular interpretation of the mechanism of action: precise targeting of tumors“Blood supply line”

Axitinib is a second-generation highly selective VEGFR inhibitor that targets VEGFR-1, VEGFR-2 and VEGFR-3, blocking tumor angiogenesis. Compared with first-generation drugs such as Sorafenib and Sunitinib, the inhibitory potency of axitinib reaches the subnanomolar level, that is, very low concentrations can significantly inhibit tumor blood vessel formation.

It can be understood as:

The first-generation drug is"generally cutting off the water supply", which may be accompanied by more side effects;

Axitinib "precisely locks the water pipe valve", which can not only prevent tumors from obtaining blood supply, but also reduce interference with normal tissues.

This precise and efficient mechanism makes it an ideal partner for immunotherapy.

xa0

5. Global Prices and Generic Drug Trends

The price of axitinib has long been a concern.

1. US market:Inlyta® (original drug, produced by Pfizer) costs about about 6,000 yuan, and there is no generic substitute.

2. Chinese market: It has been included in medical insurance. The common specifications are:14 tablets of 1mg and 28 tablets of 5mg. The price is generally 2000-3000 yuan, which significantly reduces the burden on patients.

3. Generic drug progress: Some overseas channels (such as India and Laos) have generic versions circulating, with prices as low as 1/5 of the original drug. The price is about 1,000 yuan. The price may fluctuate due to the exchange rate, and the ingredients are basically the same as the original drug.

xa0

xa0

6. Clinical efficacy and real-world evidence

In addition toKEYNOTE-426 study, other clinical and real-world data also support the efficacy of axitinib:

Analysis of East Asian population subgroup: After patients in Japan, South Korea and Taiwan received axitinib+pembrolizumab, the survival benefit was consistent with the global overall results, and there was no difference in safety. This provides stronger evidence for application in Asia.

Real-world research: Some studies have shown that patients' compliance has significantly improved after medical insurance reimbursement, and long-term efficacy is closer to clinical trial levels.

Individualized efficacy prediction: The latest research found that Patients with high T-cell-inflamed gene expression profile perform better in axitinib + pembrolizumab treatment. This provides a direction for future accurate crowd screening.

xa0

7. Daily management of patients: the key to improving quality of life

Patients often face side effects challenges during long-term use of axitinib. Scientific management is an important part of ensuring therapeutic efficacy:

Hypertension: common and controllable, blood pressure should be monitored regularly and antihypertensive drugs should be used if necessary.

Gastrointestinal reactions: such as diarrhea and nausea, can be improved through dietary adjustments and symptomatic drugs.

Hand-foot syndrome: Apply moisturizer and avoid friction to reduce discomfort.

Hypothyroidism: thyroid hormone levels need to be checked regularly and thyroid hormone supplemented if necessary.

Through the cooperation between doctors and patients, the vast majority of patients can survive with the disease for a long time and maintain a good quality of life.

xa0

xa0

8. Future prospects: Potential applications acrossRCC

The current approved indication of axitinib is limited to renal cell carcinoma, but its mechanism determines that it may be applicable to other tumors that depend on VEGF signaling. For example:

Several studies are exploring its combined use in hepatocellular carcinoma and endometrial cancer.

There are also experimental studies suggesting that it may have certain effects on vascular related diseases .

With the development of precision medicine, axitinib is expected to expand beyond renal cancer and expand more indications in the future.

xa0

Nine, Conclusion

Axitinib (Axitinib, Inlyta®) is no longer a single second-line targeted drug, but has become one of the best partners in immunotherapy. Its precise mechanism, the advantages of combination therapy, and the price turning point brought by medical insurance and generic drugs jointly determine its important position in future cancer treatment. With more real-world data and new indications explored, axitinib is expected to continue to expand its application landscape and benefit more patients.

xa0

Overseas Reference Links

Nature Medicine – Pembrolizumab plus axitinib 5-year survival and biomarker analyzes (2025)

Cancer Network – Pembrolizumab/Axitinib improves survival (2025)

EMA – Axitinib Accord approval (2024)

PubMed – Cost-effectiveness of Pembrolizumab + Axitinib (2020)

Frontiers in Oncology – European cost-effectiveness analysis (2023)

PMC – Cost-effectiveness of Avelumab + Axitinib (2020)

PubMed – KEYNOTE-426 East Asian subgroup analysis (2025)